Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?

Inter-patient heterogeneity is a major barrier to achieving the effective therapy of mesothelioma. Recent advances in genomics have illuminated the extent of genomic inter-patient heterogeneity, which has led to the development of new strategies to treat this lethal cancer. Targeting of epigenetic, and genomic aberrations involving critical tumour suppressors are now beginning to be translated in the clinic. New synthetic lethal approaches, in parallel with development of new trial designs such as master protocols, have the potential to accelerate the implementation of much-needed improvements in treatment for patients with this deadly cancer.